scientific programme
40
wednesday, 25 June 2014
S-27
SYMPOSIUM
15:00–17:00
Ballroom B
Track: Clinical
Topic: Clinical Investigator, National Fun-
ding Agency, Public-Private Partnership ini-
tiated clinical trials in the development of
novel and effective CNS drugs (C)
A new nomenclature proposal for psycho-
tropic drugs
Chair:
Stephen Stahl, USA
Co-Chair: Joseph Zohar, Israel
S-27-001
Introduction and antidepressants
Joseph Zohar, Israel
S-27-002
Anxiolytics and hypnotics
David Nutt, United Kingdom
S-27-003
Antipsychotics
Stephen Stahl, USA
S-27-004
A view on the new nomenclature from the
perspective of the drugs developed in Japan
Shigeto Yamawaki, Japan
H. Hashimoto, K. Ikeda, T. Kato, S. Kanba,
N. Ozaki, I. Kusumi
Learning Objectives:
This symposium will
discuss the introduction of a new nomencla-
ture proposal for psychotropic drugs that will
be more useful in the clinical setting where
current symptom based nomenclature is be-
come somewhat redundant as drugs are be-
ing approved.
S-28
SYMPOSIUM
15:00–17:00
Ballroom C
Track: Translational
Topic: Depression (A)
Serotonin, stress and depression: Genetic
and epigenetic factors
Chair:
Paul Albert, Canada
Co-Chair: Ramin V. Parsey, USA
S-28-001
Genetic mechanisms for longterm alterations
in serotonin in depression
Paul Albert, Canada
S-28-002
Brain serotonin 1A receptor binding in major
depressive disorder
Ramin V. Parsey, USA
G. Sullivan, J. Kaufman, C. Delorenzo, N. Hes-
selgrave, R. T. Ogden, M. Oquendo, J. J. Mann,
J. Miller
S-28-003
Stress and depression: A vicious cycle?
Catherine Belzung, France
S-28-004
The role of SLC6A4 DNA methylation in
stress-related changes in hippocampal vol-
ume: A study in depressed patients and
healthy controls
Linda Booij, Canada
M. Szyf, A. Carballedo, E.-M. Frey, D. Morris,
V. Ly, C. Fahey, J. Meaney, M. Gill, T. Frodl
Learning Objectives:
This symposium will up-
date delegates and the role of serotonin, stress
and depression and will discuss the roles of
genetic and epigenetic (environmental) fac-
tors in modulating the activity of the seroto-
nergic activity.
S-29
SYMPOSIUM
15:00–17:00
Room 11
Track: Translational
Topic: Biomarkers (including pharmacoge-
nomics and brain imaging) for diagnosis
and treatment response (C)
Clinically useful biomarkers in psychiatry:
The promise and problem
Chair:
Ian Everall, Australia
Co-Chair: Brian Dean, Australia
S-29-001
Progress toward clinically useful biomark-
ers in psychiatry
Brian Dean, Australia
S-29-002
Biomarkers for psychosis onset: Promising
candidates from the genome
Ian Everall, Australia
